Cancer discovery
-
A neoantigen derived from mutant IDH1 can promote antitumor CD4(+) T-cell and antibody responses.
-
Cancer Research UK's expanded 5-year funding strategy includes an annual award for mid-career scientists providing £1.5 million ($2.3 million) over 6 years to cover the costs of running a lab.
-
In the phase III PREVAIL study, taking enzalutamide prior to chemotherapy improved survival and slowed progression of metastatic castration-resistant prostate cancer. The FDA is now considering an application to expand the drug's use to the pre-chemotherapy setting.
-
Based on data from the key phase III REGARD trial, the FDA approved ramucirumab as second-line therapy for patients with advanced stomach cancer and gastroesophageal junction adenocarcinoma.